Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma

NCT02136134 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

498

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Myeloma

Interventions

DRUG: Daratumumab
DRUG: VELCADE (Bortezomib)
DRUG: Dexamethasone

Sponsor

Janssen Research & Development, LLC